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Abstract 
 
The Notch1 gene plays an important role in mammalian cell fate decision and 
tumorigenesis.  Upstream control mechanisms for transcription of this gene are still 
poorly understood. In a chemical genetics screen for small molecule activators of 
Notch signaling, we identified Epidermal Growth Factor Receptor (EGFR) as a key 
negative regulator of Notch1 gene expression in normal human keratinocytes, intact 
epidermis and skin squamous cell carcinomas (SCCs).  The underlying mechanism for 
negative control of the Notch1 gene in the human cells, as well as in a mouse model 
of EGFR-dependent skin carcinogenesis, involves transcriptional suppression of p53 
by the EGFR effector c-Jun.  Suppression of Notch signaling in cancer cells 
counteracts the differentiation inducing effects of EGFR inhibitors, while, at the same 
time, synergizing with these compounds in induction of apoptosis.  Thus, our data 
reveal a novel role of EGFR signaling in negative regulation of Notch1 gene 
transcription, of potential relevance for novel combinatory approaches of cancer 
therapy. 
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  Cell growth and differentiation are controlled by a complex interplay of 
signaling pathways functioning in an "integrated", rather than sequential or parallel 
fashion. Chemical Genetics is based on the principle of using small molecular weight 
compounds to abrogate or enhance specific regulatory pathways, providing a 
powerful approach to analyze complex regulatory systems.  In the present study we 
utilized this approach to probe into the signaling network involved in control of 
Notch1 gene expression and function in human keratinocytes, skin and tumors.  
 Notch signaling plays a key role in promoting keratinocyte differentiation and 
suppressing keratinocyte-derived tumors 1, 2.  Notch receptors, with Notch1 and 2 
being the main forms expressed in keratinocytes, are processed by a Ca2+-dependent 
protease in the Golgi prior to transport to the cell membrane.  Upon interaction with 
transmembrane ligands (Jagged1 and 2 or Delta1-4) expressed on the surface of 
neighboring cells, Notch receptors are activated by consecutive cleavage by an 
ADAM metalloprotease and a presenilin/-secretase complex.  The resulting Notch 
intracellular domain (ICN) translocates to the nucleus where it associates with the 
DNA binding protein CSL (CBF-1 or RBP-J in mammalian cells, converting it 
from a repressor into an activator of transcription 3. Binding of a second ancillary 
protein, Mastermind-like 1 (MAML1) or related family members, is required for 
sustained levels of Notch/CSL-dependent transcriptional activation (through 
recruitment of further transcription co-activators such as p300) 4.   
A 51 amino acid peptide (MAM51) corresponding to the amino terminal 
region (aa 13-74) of the MAML1 protein competes for MAML1 binding to the 
Notch/CSL complex, thereby preventing downstream transcription 5.  We recently 
showed that, in primary human keratinocytes, suppression of Notch signaling by this 
approach results in a lesser commitment to differentiation, expansion of stem cell 
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populations and dramatically increased susceptibility to ras-induced oncogenic 
conversion 2.  Similar effects were observed after pharmacological suppression of 
endogenous Notch activity by a -secretase inhibitor 2.  These findings are likely to be 
of clinical significance, as Notch1 gene expression and activity are substantially 
down-modulated in keratinocyte cancer cell lines and tumors, with expression of this 
gene being under positive p53 control in these cells 2, 6. 
 EGFR is among the most intensely studied and well understood determinants 
of epithelial cell proliferation, and EGFR inhibitors have surfaced as an outstanding 
example of rational-based drug design for tumors 7.  EGFR signaling is likely to 
function in the keratinocyte proliferative compartment of the epidermis as a “built-in” 
mechanism to maintain self renewal and, at the same time, suppress differentiation, in 
contrast to the upper layers where this pathway is down-modulated. In fact, 
abrogation of EGFR/ERK signaling in proliferating keratinocytes, by either chemical 
or genetic manipulations, induces differentiation, while sustained activation of this 
pathway, under conditions where it is normally down modulated, suppresses 
differentiation 8, 9. This has potentially important implications for keratinocyte-derived 
tumors, where EGFR signaling is persistently activated and promotes proliferation 10.  
At the biochemical level, little is known on the link between EGFR/ERK pathways 
and control of differentiation. Here we report a novel role of this pathway in negative 
regulation of Notch1 gene transcription in both normally proliferating keratinocytes 
and cancer, which impinges on control of differentiation as well as apoptosis.  
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Results 
 
Negative regulation of Notch1 gene expression by EGFR/ERK signaling. 
Little is known of pathways involved in upstream control of Notch1 gene 
expression and activity in keratinocytes, and mammalian cells in general. To address 
this issue we undertook a chemical genetics approach.  Rather than screening a large 
collection of unknown chemicals, we chose a library of 489 compounds, approved by 
the Food and Drug Administration (FDA) and of established target selectivity, using a 
Luciferase Notch/CSL-responsive reporter as a read-out.  The negative regulators of 
Notch signaling identified by this screen included inhibitors of metalloproteases 
(MMP) and -secretase, which are required for endogenous Notch activation 4, 
confirming the validity of the assay (suppl. Table I).  Statistical analysis of the results 
pointed to a number of other candidate pathways.  In particular, the most significant 
compounds to induce Notch activity were kinase inhibitors that target components of 
signaling networks connected with EGFR signaling, which was of special interest, 
given the relevance of this pathway in keratinocytes and cancer  11, 12.  
To validate the findings of our screen, we compared the effects of EGFR 
inhibition and stimulation on endogenous Notch signaling in human primary 
keratinocytes.  A dose-response of human primary keratinocytes to the EGFR 
inhibitor AG1478 was determined, on the basis of down-modulation of phospho-
EGFR, -ERK1/2, -Jun and -Elk levels, as well as c-Fos expression (Supplemental Fig. 
1). At the same doses, there was induction of the “canonical” Notch target genes 
Hes1, Hes5 and Herp1, while, conversely, EGF treatment suppressed expression of 
these genes (Fig. 1A).  In parallel with this effect, Notch1 mRNA levels were 
increased by EGFR inhibition, while they were down-regulated by EGF treatment 
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(Fig. 1B). Consistent with a transcriptional mechanism, no increase of Notch1 mRNA 
stability was observed in EGFR inhibitor-treated cells after Actinomycin D treatment 
(data not shown). The results were confirmed at the protein level, by immunoblotting 
of AG1478- and EGF-treated keratinocytes with antibodies against total and 
cytoplasmic activated forms of Notch1 as well as Hes1 (Fig. 1C).  Effects similar to 
those of AG1478 were also elicited by Tarceva, an EGFR inhibitor approved for 
clinical use (Collins&Workman, Nat Chem Biol 2006) (Supplemental Fig. 2).  
Besides chemical inhibition, up-regulation of Notch1 activity and expression were 
also observed after knockdown of EGFR expression by transfection of keratinocytes 
with specific siRNAs (Fig. 1D). Unlike Notch1, Notch2 expression was modulated by 
EGFR signaling at the mRNA but not protein level (Suppl. Fig. 3A; Fig. 1C), while 
no consistent changes were found in expression of the Notch ligands Jagged 1 and 
Delta like 1 (Suppl. Fig. 3B,C). 
EGFR suppression is expected to cause growth inhibition and increased 
apoptosis (Scaltrtiti, 2006, Ref. 7; Gong, Pao, PLoS Med 2007), a fact that we 
experimentally confirmed, raising the possibility that the induction of Notch1 
expression is only an indirect consequence of these events.  However, treatment of 
keratinocytes with TNF- at pro-apoptotic concentrations had no effects on levels of 
Notch1 expression, which was also not affected by suppression of keratinocyte 
growth by TGF-ß treatment (Supplemental Fig. 2) or, as we recently reported, 
increased expression of cyclin/CDK inhibitors (ANNA’s paper).  
The ERK1/2 kinases and the AP-1 transcription complex function as 
downstream effectors of EGFR activation 11. Induction of Notch1 gene expression 
similar to that caused by EGFR suppression was observed after siRNA-mediated 
knockdown of the MEK1 and ERK1 genes while, consistent with their proposed 
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distinct function in keratinocytes (Khavari Cancer Res. 2004 where they show that 
Only Mek1, however, recapitulated Ras/Raf effects in increasing proliferation and 
integrin expression while suppressing differentiation, which are impacts characteristic 
of epidermal neoplasia.), knockdown of MEK2 or ERK2 had no such effect (Fig. 1E). 
In contrast to MEK1 and ERK1, no increase of Notch1 expression, or even 
suppression, was also observed after knock-down and/or pharmacological inhibition 
of the p38 and JNK kinases, Akt and PKA (Fig. 1E and Supplemental Fig. 2).  
Induction of Notch1 expression similar to that caused by EGFR and ERK suppression 
occurred also after knockdown of c-Jun and c-Fos, two key AP-1 family members 
(Fig. 1 F,G).  Even in this case, the effects were specific, as they were not observed 
after knockdown of other AP-1 family members like JunB, Jun D and Fra1, nor of 
Elk-1, a transcription factor which is activated by EGFR activation though a separate 
mechanism from AP1 (Friday&Adjei, 2008 Clin Cancer Res.) (Fig. 1F).   
 
Modulation of Notch1 gene transcription by EGFR signaling through p53. 
We and others recently showed that the Notch1 gene is a direct transcriptional 
target of p53 in keratinocytes 2, 6 ADD MANDINOVA.  Consistent with these 
previous results, our chemical screen pointed to a p53 inhibitor, pifithrin, as a 
negative regulator of Notch signaling (suppl. Table I), a finding which we directly 
confirmed by treating keratinocytes with this compound (data not shown).  We 
therefore surmised that a p53-dependent mechanism may underlie up-regulation of 
Notch1 expression by EGFR suppression.  To test this possibility, p53 expression was 
suppressed in primary keratinocytes by siRNA knock-down.  This resulted in reduced 
levels of Notch1 expression already under basal conditions and, much more 
substantially, in response to EGFR knock-down (Fig. 2A). Consistent with a p53-
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dependent transcriptional control mechanism, luciferase reporter activity of a 2.4 kbp 
Notch1 promoter region containing p53 binding sites (but not of a shorter region 
lacking these sites) was induced in HKCs after EGFR inhibition, with such induction 
being abrogated by p53 knock-down (Fig. 2B).   
Endogenous p53 activity, as assessed by expression of well-established target 
genes, p21WAF1/Cip1 and Gadd45 13, was induced as a consequence of EGFR 
inhibition (Fig. 2C).  There was also a substantial increase of Mdm2, a negative 
regulator of p53 stability and itself a p53 target gene 13 (Fig. 2D).  Consistent with the 
negative feedback loop between p53 and Mdm2 protein expression, induction of p53 
protein expression by AG1478 became much more evident in cells concomitantly 
treated with Nutlin, an Mdm2 inhibitor 14 (Fig. 2E).   
Emerging evidence points to the importance of control of p53 activity by 
transcription of this gene (15-17 and refs. therein).  Consistent with this possibility, real 
time RT-PCR analysis showed that p53 mRNA levels were significantly increased as 
a consequence of EGFR inhibition while, conversely, were reduced by EGF treatment 
(Fig. 2F).  Previous work with mouse embryonic fibroblasts indicated that the p53 
gene can be a direct target of c-Jun-mediated transcriptional suppression 18.  In 
agreement with this conclusion, chromatin immuno-precipitation experiments showed 
specific binding of the endogenous c-Jun protein to a predicted AP-1 binding region 
of the p53 promoter in control but not EGFR-inhibitor-treated cells (Fig. 2G). 
Functionally, p53 promoter activity (Fig. 2H) as well as endogenous p53 RNA 
expression (Fig. 2I) was induced by siRNA-mediated knockdown of c-Jun, which, as 
shown before, induces Notch1 expression. A link between the two was demonstrated 
by the fact that induction of Notch1 expression by c-Jun knock-down was blocked by 
the concomitant down-modulation of p53 expression (Fig. 2J).   
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EGFR-p53-Notch control of differentiation in primary keratinocytes and intact 
skin. 
EGFR signaling provides a break to differentiation, while increased Notch 
activity promotes this process 1.  Real time RT-PCR as well as immunoblot analysis 
showed that down-modulation of EGFR signaling, by either transfection with siRNAs 
against EGFR or AG1478 treatment, induced expression of several terminal 
differentiation markers in keratinocytes, including Keratin1 and 10 and Involucrin 
(supplemental Fig. 4 and data not shown).  To assess whether induction of 
differentiation by EGFR suppression is due to up-regulation of Notch signaling, 
primary human keratinocytes were infected with a retroviral vector expressing a 51 
amino acid peptide (MAM51) that competes for MAML1 binding to the Notch/CBF-1 
complex, thereby preventing downstream transcription 5. Treatment of MAM51-
expressing keratinocytes with AG1478 caused a similar induction of Notch1 
expression as control cells; by contrast, induction of Hes1 and differentiation markers 
was suppressed (Fig. 3A).  Chemical inhibitors of -secretase activity like DAPT 
suppress proteolysis-dependent activation of endogenous Notch receptors 19. As with 
MAM51 expression, treatment of primary keratinocytes with DAPT counteracted 
induction of Hes1 and differentiation marker expression caused by EGFR down-
modulation (Fig. 3B).  Similar counteracting effects were also observed after siRNA-
mediated knock-down of Notch1 and p53 expression, indicating that up-regulation of 
these genes by EGFR inhibition is responsible for the observed induction of 
differentiation (Fig. 3C). A more indirect downstream mechanism, like that reported 
in Drosophila with EGFR signaling suppressing Groucho-dependent transcription  20, 
is unlikely in our system.  In fact, consistent with our previous findings, EGFR 
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activation exerted no counteracting effects on induction of differentiation by activated 
Notch1 (Fig. 3D) and increased Hes1 expression, a mammalian Groucho effector 21, 
suppressed rather then induced differentiation (Fig. 3E), confirming what previously 
observed for Hes1 effects in mouse primary keratinocytes 31.   
 Growth/differentiation control of keratinocytes in culture is likely to differ in 
significant aspects from control of these cells in intact skin.  For further validation of 
our findings, we resorted to several complementary approaches.  For the first, mice 
with a GFP reporter for Notch activity were injected with the EGFR inhibitor 
AG1478.  Immunofluorescence analysis showed significantly elevated GFP 
expression in the epidermis of the AG1478 treated mice versus the control (Fig. 4A). 
For confirmation and quantification of the results, the epidermis of these mice was 
separated from the underlying dermis by a brief heat treatment, followed by total 
RNA preparation and real time RT-PCR analysis.  This confirmed increased GFP 
expression, which paralleled increased expression of the endogenous Notch1, p53 and 
Keratin 1 genes (Fig. 4B,C).  As a second approach, the epidermis of homozygous 
mice for a hypomorphic EGFR mutation was analyzed, in parallel with heterozygous 
littermates.  Even in this case, decreased EGFR activity was found to result in 
increased p53 and Notch1 expression (Fig. 4D).   
 In the human situation, inhibitors of the EGFR pathway are now used in 
clinical treatment of several types of cancer (REF : Scaltrtiti, 2006, Ref. 7; 
Collins&Workman, Nat Chem Biol 2006) Immunofluorescence analysis of skin 
biopsies from a cohort of melanoma patients treated with the MEK inhibitor 
AZD6244 in parallel with age and sex matched control showed a significant up-
regulation of Notch1 expression (Fig. 4E), which paralleled that of p53 (REF : Schad 
K, Baumann Conzett K, Enderlin V, Ziepser M, Cantarini M, Nief M, French LE, 
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Dummer R, J clin Oncol 2008 Continuous MEK inhibition by AZD6244 (ARRY-
142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles 
senescence driven skin aging and data not shown). Similar results were obtained with an 
organ culture system of freshly excised human skin, using an optimized method that 
allows maintenance of viable tissue with no sign of degeneration and/or altered 
differentiation for up to 7 days (our unpublished observations).  
Immunohistochemical as well as real time RT-PCR analysis indicated that, even in 
these conditions, EGFR inhibition caused a parallel induction of Notch1 activity and 
expression, and differentiation in keratinocytes, together with p53 and p21WAF1/Cip1 
(Fig. 4F, Supplemental Fig. 5).  Using this approach, we tested whether the increase 
in keratinocyte differentiation is Notch dependent.  For this, human skin cultures were 
treated with AG1478 plus/minus DAPT.  As shown in Fig. 4G, induction of Keratin 1 
and Involucrin expression by EGFR inhibition was counteracted by the concomitant 
treatment with the Notch / -secretase inhibitor, while, as expected, induction of the 
Notch1 gene itself, or of p53, was unaffected or even increased.  
 
Inhibition of EGFR signaling in cancer cells induces Notch1 gene expression 
through p53. 
To assess whether the p53/Notch regulatory loop discovered here applies to 
conditions where increased EGFR signaling has been causally linked with cancer 
development, we analyzed transgenic mice expressing a constitutive active form of 
the EGFR/Ras adaptor protein SOS under control of a keratin 5 promoter (K5-SOS-
F).  These mice develop spontaneous skin tumors strictly dependent on the presence 
of functional EGFR 22. In K5-SOS-F transgenics with a concomitant keratinocyte-
specific deletion of the c-Jun gene, skin tumor development is impaired, correlating 
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with reduced EGFR expression and increased differentiation 23.  The present results 
suggested that EGFR/c-Jun regulation of p53 and Notch1 expression may also be 
involved.  In fact, real time RT-PCR analysis showed significantly higher levels of 
Notch1 and p53 expression in the small tumors formed by K5-SOS-F transgenic mice 
with epidermal deletion of the c-Jun gene (c-Junep SOS+) relative to tumors formed 
in K5-SOS-F transgenics with the intact c-Jun gene (c-Junf/f SOS+) (Fig. 5A).  These 
data were confirmed at the protein level by immunoblot analysis of a separate set of 
tumors, as well as by immunofluorescence for Notch1 expression (Fig. 5B, C).  
To assess whether similar EGFR regulation of Notch1 expression applies to 
human cancer, keratinocyte-derived SCC cells (SCCO28, SCC12 and SCC13) with 
wild type p53 (http://www.sanger.ac.uk/genetics/CGP/CellLines/) were treated with 
EGFR inhibitor.  Besides mutations, p53 activity can also be reduced in tumors as a 
consequence of decreased p53 gene transcription 17, 24-27.  Consistent with this mode 
of regulation, EGFR inhibition of SCC cells induced expression of the p53 gene as 
well as of p21WAF1/Cip1, indicative of increased p53 activity (Fig. 6 A,B).  This was 
paralleled by a substantial increase of Notch1 mRNA and protein levels and 
differentiation markers (Fig. 6C,D: Supplemental Fig. 6A). As with primary 
keratinocytes, p53 knockdown experiments showed that even in cancer cells, 
induction of Notch1 expression by EGFR-inhibition is p53-dependent (Fig. 6E).  
Cancer cell lines can differ substantially in their control mechanisms from 
cells in primary tumors.  Therefore, as a further validation of our findings, the same 
organ culture system described above for intact skin was adapted to the analysis of 
clinically occurring SCCs freshly excised from patients.  The dissected more 
homogeneous parts of tumors were cut into small pieces of the same size (2x2 mm), 
and placed into multi-well dishes as for skin organ cultures.  In five independent 
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tumors, EGFR inhibition resulted in reduction of c-Fos expression, indicative of 
EGFR signaling suppression, and concomitant induction of Notch1, p53 and Keratin 1 
(Fig. 6F; Supplemental Fig. 6C). In four other tumors no such effects were observed, 
consistent, in two cases, with resistance of EGFR inhibition (as assessed by no 
decrease in c-Fos expression) and, in the other two, undetectable p53 expression or 
activity (data not shown).  
 
Inhibition of Notch signaling in cancer cells suppresses differentiation induced 
by EGFR suppression while it synergizes for apoptosis. 
 
As with primary keratinocytes, even in SCC cells inhibition of EGFR signaling 
caused up-regulation of differentiation markers expression, through a Notch dependent 
mechanism (Supplemental Fig. 6A,B).  We have recently found that Notch-dependent 
differentiation of keratinocytes render these cells more resistant to apoptosis (REF 
Mandinova et al.).  Thus, an attractive possibility was that suppression of Notch 
signaling, while suppressing the pro-differentiation effects of EGFR inhibitors, may 
synergize with these compounds in triggering apoptosis.  To assess this possibility, 
SCC cells were treated with DAPT plus-minus EGFR inhibitor.  As shown in Fig. 7A, 
the concomitant treatment led to a substantial increase of apoptosis.  These findings 
were paralleled by a synergistic induction of Bim1 expression (Fig. 7B), a pro-
apoptotic Bcl2 family member that has been recently implicated in the response of 
cancer cells to EGFR inhibitors 28. 
To further validate the relevance of these findings for the behavior of cancer in 
vivo, immune-compromised mice were injected with SCC cells expressing the Notch 
inhibitory MAM51 peptide, in parallel with control cells.  After formation of sizable 
tumors (4 weeks after injections), mice were treated with AG1478 for a week.  RT-PCR 
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analysis of tumor RNAs showed substantially higher levels of Hes1 and differentiation 
marker expression in tumors formed by control than MAM51-expressing cells, while 
levels of Bim1 were oppositely regulated (Fig. 7C).  This was paralleled by a higher 
apoptotic fraction in tumors with suppressed Notch signaling (Fig. 7D). 
 
Discussion 
 
Loss- and gain-of function experiments in mice as well as work with human 
keratinocytes have established that EGFR signaling plays a key role in positive 
control of keratinocyte growth potential and carcinogenesis 10.  A similar role has 
been found for downstream effectors of this pathway at the level of transcription, like 
c-Jun 9.  Besides enhancing proliferation, we have shown here that EGFR signaling 
plays a significant role in suppressing differentiation through negative regulation of 
Notch1 gene expression and activity.  This mechanism is likely to provide a break for 
the commitment to differentiation of keratinocytes in the basal proliferative 
compartment of the epidermis as well as in cancer, where EGFR signaling is 
characteristically elevated 10. 
In the upper epidermal layers, EGFR signaling is normally down-modulated 
and therefore ceases to be relevant.  In fact, differentiation of keratinocytes as they 
migrate to the upper epidermal layers is induced by multiple EGFR-unrelated events 
including, most notably, loss of integrin-mediated adhesion to the matrix and 
establishment of cadherin-dependent cell-cell adhesion 29.  This is consistent with 
control of the Notch1 gene by EGFR signaling – via p53 - being relevant for the 
behavior of proliferating keratinocytes in normal skin and cancer, while additional 
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multiple mechanisms are responsible for the increase of Notch signaling in normally 
differentiating keratinocytes of the upper epidermal layers 1.  
We have shown that suppression of the EGFR signaling cascade leads to up-
regulation of Notch1 gene expression through a mechanism involving transcriptional 
up-regulation of the p53 gene.  Previous studies pointed to NF-B control of p53 gene 
expression 30, which could be of relevance to the present situation, as NF-B activity 
is induced in keratinocytes with differentiation 31, while its suppression promotes 
tumor development 32.  However, expression of NF-B responsive genes, as an 
indication of endogenous activity, is not induced in keratinocytes by EGFR 
suppression (data not shown).  As an alternative mechanism, we have found that 
control by AP-1 family members is involved.  AP-1 is a heterodimeric DNA-binding 
complex formed by proteins of the c-Jun and c-Fos families, which differ in their 
ability to activate target genes and can also function in an inhibitory fashion 33.  
Previous work with mouse embryo fibroblasts has indicated that c-Jun can be a direct 
negative regulator of p53 gene expression 18.  Consistent with this conclusion, we 
have found that endogenous c-Jun binds to the p53 promoter in both normal and SCC-
derived keratinocytes, and that expression of the p53 gene in these cells is enhanced 
by c-Jun knock-down.  Notch1 expression is also induced by c-Jun knockdown, in a 
p53-dependent fashion.  This concomitant mode of regulation of p53/Notch1 
expression by EGFR signaling was further validated by our findings with organ 
cultures of intact human skin and SCCs, as well as a mouse model of skin cancer 
formation dependent on EGFR and c-Jun function. 
EGFR has become an important target of cancer drug design, and several 
selective EGFR inhibitors have now been approved for clinical use.  Recent data have 
highlighted the fact that inhibitors directed to critical receptors like EGFR utilize the 
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cell death pathway for inducing tumor regression 28. However, the exact molecular 
mechanisms underlying sensitivity and resistance of tumor cells to EGFR inhibition - 
including the contribution of other integrated pathways like the ones we have 
identified here - remain to be elucidated 34. Importantly, suppression of Notch 
signaling in squamous carcninoma cells counteracts the differentiation inducing 
effects of EGFR inhibitors, while, at the same time, synergizing with these 
compounds in induction of apoptosis.  Other ongoing studies in the laboratory 
indicate that the enhancing effects of Notch suppression on apoptosis may extend also 
to lung cancer cells.  This suggests an attractive new avenue of combination 
approaches for cancer therapy that may enhance the potency of EGFR inhibitory 
agents on tumors, while at the same time ameliorating their well known toxic effects 
on the skin which have been attributed, at least in part, to aberrant differentiation 12.   
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Methods  
 
Cell culture and viruses. 
Culturing of primary human keratinocytes and SCC 12, 13 and 028 cells, and 
infection with the MSCV-MAM51 5 and control retrovirus were as previously 
reported 2. Adenoviruses for Notch1, Hes1 and GFP and adenoviral infections were 
previously described 31. NCI-H1299 and NCI-H1299 were cultured in RPMI medium 
(Invitrogen) supplemented with 10% bovine serum. Chemical inhibitors, AG1478 
(LC Labs), Nutlin (Calbiochem), DAPT (Calbiochem), ERK inhibitory peptide-cell 
permeable (Calbiochem) were dissolved in DMSO and applied at the indicated 
concentrations.  For knock down experiments, cells were transfected as described 31 
with validated stealth siRNAs for human EGFR, p53, and c-Jun in parallel with 
corresponding Stealth siRNA controls (Invitrogen), or ERK1, ERK2 and Notch1 
(GeneGlobe, Qiagen) and analyzed 48-72 hours after transfection. 
 
Quantitative real time RT PCR, chromatin immunoprecipitation and immunodetection 
techniques.  
Conditions for real time PCR analysis, chromatin immunoprecipitation Chip), 
immunoblotting and immunofluorescence were as previously described 2.  The list of 
gene-specific primers is provided in Supplemental Table II.  We used the following 
antibodies: Notch1 (Santa Cruz, C-20), activated Notch1 (Cell Signaling), Hes1 
(Chemicon AB5702), Keratin1 (Babco AF87), Involucrin (Babco PRB140C), EGFR 
(Cell Signaling), p53 (Cell Signaling), MDM2 (Cell Signaling), Integrin 4 (Santa 
Cruz), -Tubulin (Sigma GTU87), for immunoblotting for mouse proteins: Notch1 
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(Pharmingen), p53 (Novacastra), c-Jun (Transduction Labs) and Actin (Sigma), c-Jun 
for Chip assays (Santa Cruz, H79). 
 
Organ cultures 
Discarded human skin samples from abdominoplasty procedures were 
obtained from the Centre Hospitalier - Universitaire Vaudois (Lausanne, Switzerland) 
under patients’ agreement and institutional approval.  Skin samples, sterilized in 70% 
ethanol and cut, after removal of subcutaneous fat, into 1x1cm pieces, were placed in 
keratinocyte serum-free medium (KSF, GIBCO-BRL) supplemented with epidermal 
growth factor (EGF) and bovine pituitary extract (BPE), in 0.25% agar (Sigma).  The 
epidermis was maintained at the air-medium interface.  For RNA collection, skin 
samples were placed in preheated PBS at 60 °C for 45 seconds, then chilled (on ice) 
in 0.1M PBS for 1 minute, followed by mechanical separation of epidermis and 
dermis.  The epidermis was homogenized in TRI Reagent (Sigma) for RNA 
preparation.  Human SCC samples were obtained as discarded material from Mohs 
micrographic surgery at Massachusetts General Hospital (Boston, MA) with patients’ 
and institutional approvals. Tumor samples were sterilized in 70% ethanol, cut into 
pieces of approximately 2x2 mm and placed in semi-solid medium similarly to skin 
organ cultures. 
 
Tumorigenicity assays  
For in vivo tumorigenicity assays, control and MAM51 expressing SCCO28 
cells were brought into suspension, admixed with Matrigel (BD Biosciences), and 
injected (5x106 cells/injection) subcutaneously in 8 weeks old female athymic nude 
mice. Four weeks later animals were treated three times (every other day) with 
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AG1478 (1 mg/animal, dissolved in 200 l 50% DMSO:DMEM) or DMSO vehicle 
control by i.p. injections.  Mice were sacrificed 2 days after the last treatment and 
tumors processed for RNA preparation and analysis.  
 
TUNEL Assays 
Cells were trypsinized, recovered by centrifugation at 300 g and fixed in 2% 
paraformaldehyde in PBS for 16 h. Permeabilization and enzymatic labeling with 
TMR red-conjugated-dUTP were performed according to the manufacturer's protocol 
(Roche, IN). The percentage of cells that incorporated the fluorescence-conjugated 
dUTP was determined by flow cytometry. TUNEL assay on histological sections was 
analyzed with fluorescent microscopy and IPLab software. 
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Figure Legends 
 
Fig. 1. Negative control of Notch1 activity and expression by EGFR/ERK/AP1 
signaling. A and B :  Primary human keratinocytes (HKCs) were treated with 
AG1478 at the indicated concentrations or with recombinant EGF (1.0 ng/ml) for 24 
hours.  Hes1, Hes5 and Herp1 (CHANGE NAME IN THE FIG. FROM HEY2 TO 
HERP1) (A) and Notch1 (B) mRNA levels were quantified by real-time RT-PCR.  
Values are expressed as relative units after internal normalization for 36BP4 mRNA 
levels, with similar results being obtained after normalization for -actin mRNA.  C : 
HKCs were treated with AG1478 and EGF as in the previous panel, followed by 
immunoblot analysis for Hes1, total and activated Notch1, Notch2, and -Tubulin as 
equal loading control. D : HKCs were transfected with two different siRNAs specific 
for EGFR in parallel with scrambled siRNA control.  Expression of the EGFR, Hes1 
and Notch1 genes was assessed, 48h after transfection, by real time RT-PCR analysis 
(left panels), and confirmed at the protein level by immunoblotting (right panels). E 
and F : HKCs were transfected with validated siRNAs for the indicated protein kinase 
(E) and transcription factor (F) genes, in parallel with scrambled siRNA control. 
>80% knock down efficiency was obtained for each of these genes, as verified by real 
time RT-PCR analysis with the corresponding specific primers 48h after transfection 
(data not shown).  Levels of Notch1 mRNA expression were assessed by real time 
RT-PCR analysis as in the previous panels. For ERK1, ERK2, c-Jun, c-Fos and 
ELK1, similar results were obtained after transfection with a second set of specific 
siRNAs. G : HKCs, transfected with siRNA specific for c-Jun and scrambled siRNA 
control as in the previous panel, were analyzed by immunoblotting for total Notch1 
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and -Tubulin as equal loading control.  Data were quantified by densitometric 
scanning, using the -Tubulin signal for normalization (right panel). 
 
Fig. 2. Suppression of EGFR signaling induces Notch1 expression through p53.  
A : HKCs were transfected with siRNAs specific for p53 plus/minus siRNAs for 
EGFR in parallel with scrambled siRNA control.  Cells were analyzed 48 hours after 
transfection. “Knock down” of p53 expression was confirmed by real time RT-PCR 
and immunoblot analysis (left panels). Hes1 and Notch1 expression was assessed by 
real time RT-PCR as for the previous experiments.  B : HKCs were infected with the 
lentiviral reporter vectors pTRH4-N1-2.4 (N1-2.4) and pTRH4-N1-0.4 (N1-0.4), 
carrying an internal luciferase gene driven by either a 2.4 or 0.4 kb region of the 
human Notch1 promoter (nucleotides -2472 to -1 and -392 to -1 from the initiation 
codon, respectively), which contains and lacks, respectively, the mapped p53 binding 
sites (REF : Lefort 2007, Mandinova 2008).  The pTRH4 vector, carrying the 
luciferase gene devoid of exogenous promoter, was used as control.  HKCs stably 
infected with these viruses were transfected with siRNAs specific for p53 or 
scrambled siRNAs, followed by treatment (for 24 hours) with AG1478 (2 M) or 
DMSO control, as indicated. For each set of cells, values are expressed as relative 
luciferase activity after protein normalization. C : HKCs were treated with AG1478 (2 
M) or DMSO control for 24 hours, followed by real time RT-PCR analysis of 
p21WAF1/Cip1 and Gadd45 expression. D : HKCs treated with AG1478 or DMSO as 
in the previous experiments, were analyzed by immunoblotting with antibodies 
against Mdm2, and -Tubulin as equal loading control.  E : HKCs were treated with 
AG1478 and Nutlin (2 M) for 24 hours, individually and in combination, followed 
by immunoblot analysis of p53 and -Tubulin expression.  F : HKCs were treated 
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with AG1478, transfected with EGFR-specific siRNA, or stimulated with EGF as in 
the previous experiments, and analyzed, in parallel with the corresponding controls, 
for levels of p53 mRNA expression by real time RT-PCR. G : HKCs were treated 
with AG1478 or DMSO control for 24 hours.  Cells were then processed for 
chromatin immunoprecipitation analysis (ChIP) with an antibody against c-Jun and 
purified rabbit IgG as non-immune control. Real-time PCR of a distinct region of the 
human p53 gene promoter containing several conserved AP-1 binding sites (around 
position -2.6 kb, Site A in the map above) was performed along with PCR of a more 
downstream region devoid of such sites (around position -0.3 kb, Site B). The primers 
used to amplify these p53 promoter regions are listed in Supplemental Table II. H : 
cells were co-transfected with the p53n-Luc reporter plasmid (Dalla-Favera REF), 
carrying a luciferase gene driven by a 2 kb region of the human p53 promoter, 
together with siRNAs against c-Jun and analyzed for luciferase activity 48h later. For 
each set of cells, values are expressed as relative luciferase activity after protein 
normalization. I : HKCs were transfected with siRNAs against c-Jun in parallel with 
scrambled siRNA control (as in Fig. 1F,G) followed by measurement of p53 
expression by real time RT-PCR.  J : HKCs were transfected with siRNA against c-
Jun either alone or in combination with siRNA against p53, in parallel with scrambled 
siRNA control.  Notch1 expression was determined by real time RT-PCR as before. 
 
Fig. 3. Down-modulation of EGFR signaling induces keratinocyte differentiation 
through a Notch dependent mechanism.  A : HKCs infected with a retrovirus 
expressing the dominant negative MAM51 peptide or GFP control (black and white 
bars, respectively) were  treated with AG1478 (2 M) or DMSO control for 24 hours.  
Expression of the Notch1, Hes1, Keratin 1 and Involucrin genes was assessed by real 
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time RT-PCR.  B :  HKCs were treated with AG1478 (2 M) and DAPT (10 M) or 
DMSO control for 24 hours, followed by real time RT-PCR analysis of Hes1, Keratin 
1 and Involucrin expression (left panel).  Similarly treated cells were also analyzed 
for Keratin1 protein expression by immunoblot analysis, with -tubulin as equal 
loading control (right panels).  C : HKCs were transfected with Notch1 or p53 
specific siRNAs in parallel with scrambled siRNA control (black and white bars, 
respectively) and treated with AG1478 (2 M) or DMSO followed by RT-PCR for 
Keratin1. “Knock down” of Notch1 expression was confirmed by real time RT-PCR 
and immunoblot analysis (left panels).  D : HKCs were transduced with adenoviruses 
expressing activated form of Notch1 or GFP control and 24 h after infection 
stimulated with EGF (1 ng/ml). Expression of Keratin1 was assayed by RT-PCR 
analyses. E : HKCs were transduced with adenoviruses expressing Hes1 or GFP 
control followed by RT-PCR analysis of Keratin1. 
 
Fig. 4. Suppression of EGFR signaling induces p53 and Notch1 expression in 
intact mouse and human epidermis. A : Trangenic mice expressing a GFP reporter 
gene from a Notch/CBF1-responsive promoter (Mizutani, Gaiano Nature, 2007) were 
injected intraperitoneally with AG1478 (1 mg, in 100 l 75% DMSO) or DMSO 
control every two days. 6 days later, mice were analyzed for GFP expression by 
immunofluorescence of back skin sections using anti-GFP antibodies. B and C : Back 
skin of the same mice as in the previous panel was isolated and the epidermis was 
separated from the underlying dermis by a brief heat treatment.  Expression of the 
GFP transgene, as well as of the endogenous Notch1, p53 and keratin 1 genes was 
determined by real time RT-PCR, using ß-Actin for internal normalization.  D : Back 
skin epidermis of homozygous wa-2 mice (carrying a point mutation of the EGFR 
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gene resulting in a > 90% fold decrease of EGFR activity, ref .N C Luetteke, H K 
Phillips, T H Qiu, N G Copeland, H S Earp, N A Jenkins, and D C Lee GENES & 
DEVELOPMENT 8:399-413, 1994) and heterozygous littermates was analyzed in 
parallel for endogenous p53 and Notch1 expression by RT-PCR as in the previous 
panel. E : skin biopsies from a cohort of melanoma cancer patients following 
treatment with the MEK inhibitor AZD6244 (ARRY-142886; ASTRA Zeneca) were 
analyzed, in parallel with biopsies from age- and gender-matched controls retrieved 
from the same body region, for expression of Notch1 expression by 
immunofluorescence analysis with anti-Notch1 antibodies. Same exposure and image 
capture conditions were utilized for all samples.  In parallel with the increased Notch1 
expression, immunostaining with anti-p53 antibodies demonstrated increased levels of 
this protein (REF : Schad K, Baumann Conzett K, Enderlin V, Ziepser M, Cantarini M, 
Nief M, French LE, Dummer R, J clin Oncol 2008 and data not shown). (F) : Freshly 
excised human skin samples were placed in semisolid medium and treated with 
DMSO control or AG1478 (10 M) for 24h.  Histological sections were analyzed by 
immunofluorescence with antibodies against the Notch1 protein.  Arrows indicate the 
outermost layer of the epidermis and dotted line the innermost. H&E staining and 
immunofluorescence of parallel sections with anti-Keratin1 antibodies are shown in 
supplemental Fig. 5A. B : Freshly excised human skin samples, as in the previous 
panel, were placed in semisolid medium and treated with DMSO or AG1478 (10 M) 
plus/minus DAPT (10 M) (black and white bars, respectively) for 24h. The 
epidermis was separated from the underlying dermis by a brief heat treatment (60oC, 
45”) followed by total RNA preparation and analysis of mRNA expression of the 
indicated genes by real time RT-PCR, using ß-actin mRNA for normalization. 
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Fig. 5.  Differential Notch1 and p53 expression in the EGFR-dependent SOS-
mouse skin tumor model plus/minus c-Jun deletion.  A : Tumors formed by two 
K5-SOS-F transgenic mice with an intact c-Jun gene (Junf/f SOS+) and from two 
transgenics with a concomitant keratinocyte-specific deletion of the c-Jun gene (c-
Junep SOS+) were analyzed by real time RT-PCR for levels of Notch1 and p53 
expression (left and right panels, respectively), using ß-actin for normalization.  B : 
Extracts from another set of tumors, from three mice per genotype, was analyzed by 
immunoblotting with antibodies against the indicated proteins.  C : 
Immunofluorescence / confocal analysis with anti-Notch1 antibodies of tumors 
formed by K5-SOS-F transgenics plus-minus c-Jun deletion.  Hoechst staining was 
used for cell identification.   
 
Fig. 6. EGFR-dependent regulation of p53 and Notch in cancer cell lines and 
human squamous cell carcinomas (SCCs).  A - C: SCC12, SCC13 and SCCO28 
cells, treated with AG1478 (2 M) versus DMSO control for 24 hours, were analyzed 
for levels of p53 (A), p21WAF1/Cip1 (B), and Notch1 (C) expression by real time RT-
PCR. D : SCCO28 cells were treated with AG1478 at the indicated concentrations for 
24h followed by immunoblot analysis for Notch1 and -Tubulin as equal loading 
control. E : SCCO28 cells were transfected with p53-specific siRNA in parallel with 
scrambled siRNA control followed, 24 hours later, by treatment with AG1478 or 
DMSO for 24 hours.  Real time RT-PCR was used to determine resulting levels of 
Notch1 expression, as well as to verify p53 knockdown (not shown). F : Surgically 
excised squamous cell carcinomas from five different patients (SCC1, 2, 3, 4, 5) were 
cut into small pieces of similar size, placed in semisolid medium and treated with 
AG1478 (10 M) or DMSO control for 24 hours.  Real time RT-PCR was used to 
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measure expression of Notch1 and p53.  Analysis of c-Fos (as a measure of response 
to EGFR inhibition) and keratin 1 expression in these tumors is shown in 
supplemental Fig. 6C.  
 
Fig. 7. Enhanced apoptosis in squamous carcinoma cells by concomitant 
suppression of EGFR and Notch signaling. A :  SCC13 and SCCO28 cells were 
treated with DMSO, AG1478 (5 M), DAPT (20 M) alone or in combination for 72 
h. Cells were analyzed by TUNEL assays and flow cytometry.  Values represent the 
average percentage of apoptotic cells from 3 independent experiments SD.  B : 
SCC13 and SCCO28 cells, treated as in previous panel, were analyzed for expression 
of the pro-apoptotic gene Bim1 by RT-PCR. C : SCC formation was induced in nude 
mice by subcutaneous injections of SCCO28 cells expressing MAM51 or GFP control 
(black and white bars, respectively).  To minimize individual animal variations, each 
mouse was injected in parallel, on the right and left flank respectively, with the two 
kinds of cells.  Four weeks after injections, the tumor bearing mice were treated three 
times, every other day, with AG1478 (1 mg/animal, mice A1, A2, A3). RNA isolated 
from tumor tissues were analyzed by real time RT-PCR for expression of the 
indicated genes. D : Frozen sections from the same surgically excised tumors as in the 
previous panel were analyzed by TUNEL labeling.  The fraction of TUNEL positive 
cells was determined in four different microscopy fields per tumor, using LPLab 
software.  Average percentage of apoptotic cells SD is represented.  The statistical 
significance of the observed differences was calculated by Ttest (P<0.05).  
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Supplemental Fig. 1. Dose dependent inhibition of EGFR signaling by AG1478. A : 
Primary human keratinocytes (HKCs) were treated with AG1478 for 24h at the indicated 
concentrations, followed by immunoblot analysis for phospho- and total EGFR, ERK1/2, 
cJun, ELK1, with -Tubulin as equal loading control.  B : HKCs treated as in the previous 
panel were analyzed for levels of c-Fos expression by RT-PCR. mRNA levels are 
expressed as relative values after normalization for 36B4. 
 
Supplemental Fig. 2.  Specific induction of Notch1 expression and activity by 
inhibition of EGFR activity. A : HKCs were treated with the EGFR inhibitor Tarceva 
(1.0 M) in parallel with inhibitors for PDGFR (XXX), PKA (YYY) and p38 (YYY), (at 
10 M concentration), for 24 hours. Parallel cultures were also treated with TNF (50 
ng/ml) or TGF ($$ ng/ml) for 24 hours.  Levels of Hes1 and Notch1 expression were 
determined by real-time RT-PCR with 36B4 for normalization. 
 
Supplemental Fig. 3. Impact of EGFR signaling on Notch2, Jagged1 and Delta like1 
expression. A : HKCs were treated with either DMSO or AG1478 at the indicated 
concentrations or EGF (1ng/ml) for 16 hours. Expression of Notch2 was analyzed by real 
time RT-PCR with -Actin mRNA for normalization. B, C : HKCs were treated with 
either EGF (1 ng/ml) or AG1478 (2 µM) and mRNA levels of Jagged1 (Jag1) and Delta 
like 1 (Dll1) were determined by real time RT-PCR as in the previous panel. 
 
Supplemental Fig. 4. Down-modulation of EGFR signaling induces keratinocyte 
differentiation. HKCs were transfected with EGFR-specific siRNAs (+) in parallel 
with scrambled siRNAs control (-).  Cells were analyzed for expression of the 
Keratin1, 10 and Involucrin differentiation markers by real time RT-PCR and 
immunoblotting (left and right panels, respectively). 
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Supplemental Fig. 5. Inhibition of EGFR signaling induces Notch1 expression 
and keratinocyte differentiation in human epidermis. A : Freshly excised human 
skin samples were placed in semisolid medium and treated with DMSO control or 
AG1478 (10 M) (upper and lower panels, respectively) for 24 hours.  Histological 
sections were analyzed by H&E and immunofluorescence with antibodies against 
Keratin1 proteins. Arrows indicate the outermost layer of the epidermis and dotted 
line the innermost. B : The epidermis of human skin samples treated as in the 
previous experiment was separated from the underlying dermis by a brief heat 
treatment (60oC, 45”) followed by total RNA preparation and analysis of mRNA 
expression of the indicated genes by real time RT-PCR, using ß-actin mRNA for 
normalization.  
 
Supplemental Fig. 6. EGFR inhibition in SCC cell lines and tumors promotes 
differentiation. A : SCC028, SCC12 and SCC13 cells were treated with AG1478 (2.0 
M) for 24h. Keratin1 and Involucrin mRNA expression was analyzed by real time RT-
PCR analysis, with ß-actin mRNA levels for normalization. B : SCCO28 cells infected 
with the retrovirus expressing the dominant negative MAM51 peptide or GFP control 
were treated with AG1478 (2 M) or DMSO control for 24 hours.  Keratin1 
expression was measured by real time RT-PCR. C : Surgically excised squamous cell 
carcinomas from five different patients (SCC1, 2, 3, 4, 5) were placed in semisolid 
medium and treated with AG1478 (10 M) or DMSO control for 24 hours as 
described in Fig. 6F.  Real time RT-PCR was used to measure expression of c-Fos (as 
a measure of response to EGFR inhibition) and keratin 1 expression.  
 
